Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MRK stock price vs GE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GE's multiple
Needs GE P/E.
Implied fair value · at MRK's multiple
Needs MRK P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Merck & Co., Inc. · implied price per share
Bear
$49.07
Base
$60.10
Bull
$74.45
GENERAL ELECTRIC COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
MRK vs PFE
Johnson & Johnson
MRK vs JNJ
Eli Lilly and Company
MRK vs LLY
Bristol-Myers Squibb Company
MRK vs BMY
AbbVie Inc.
MRK vs ABBV
AMGEN INC
MRK vs AMGN
MORGAN STANLEY
MRK vs MS
EMERSON ELECTRIC CO
MRK vs EMR
3M CO
MRK vs MMM
CUMMINS INC
MRK vs CMI
HONEYWELL INTERNATIONAL INC
MRK vs HON
LOCKHEED MARTIN CORP
MRK vs LMT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MRK can re-rate closer to GE without needing GE-style growth or leverage, then consider MRK as the cheaper relative-value option because it trades at 17.9x P/E versus GE’s 44.2x while carrying far lower leverage.
MRK trades at a clear discount to GE on both earnings and sales-based multiples, which argues for relative valuation support. The model’s implied price of $322.03 implies 147.3% upside from MRK’s current $130.20, but that appears aggressive versus GE and history context provided.
Supporting Metrics
